Thanks for posting bigdish
CONCLUSIONS
30 mg IMP321 is the RPDT in combination with weekly paclitaxel as a first line chemotherapy treatment of MBC.
6 and 30 mg IMP321 are safe and well tolerated in combination with weekly paclitaxel
IMP321 in combination with paclitaxel shows encouraging DCR (87%)
IMP321 leads to sustainable (> 6months) increase and activation of APC’s (primary PD)
IMP321 leads to sustainable (> 6months) increase in CD8 T Cell and NK cell numbers, together with an improved pre-dose Th1 status ( secondary PD).
This should get the party started. Good luck to all.
ASCO Poster Presentation, page-2
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.040(11.0%) |
Mkt cap ! $588.3M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 40.5¢ | 36.8¢ | $1.822M | 4.681M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19739 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 45420 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |